Skip to content

PROPHYLACTIC INTRAVENOUS KETAMINE, ONDANSETRON AND PETHIDINE IN PREVENTING PERIOPERATIVE SHIVERING IN PATIENTS UNDERGOING ELECTIVE KNEE REPLACEMENT SURGERY UNDER SPINAL ANAESTHESIA: A RANDOMIZED PARALLEL-GROUP, PLACEBO CONTROLLED COMPARATIVE STUDY.

PROPHYLACTIC INTRAVENOUS KETAMINE, ONDANSETRON AND PETHIDINE IN PREVENTING PERIOPERATIVE SHIVERING IN PATIENTS UNDERGOING ELECTIVE KNEE REPLACEMENT SURGERY UNDER SPINAL ANAESTHESIA: A RANDOMIZED PARALLEL-GROUP, PLACEBO CONTROLLED COMPARATIVE STUDY.

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
DRKS
Registry ID
DRKS00023440
Enrollment
216
Registered
2020-11-02
Start date
2015-11-19
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post spinal shivering R68.0

Interventions

Group 1: 0.9% normal saline 10 ml i.v. Group 2: ondansetron 4mg i.v Group 3: Ketamine 0.25mg/kg body weight i.v Group 4: pethidine 0.25mg/kg i.v

Sponsors

Army Hospital R&R Delhi India
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists (ASA) physical status I or II], aged (18-75 years), scheduled for Total Knee Replacement surgical operations under spinal anesthesia

Exclusion criteria

Exclusion criteria: 2. Exclusion Criteria included patient refusal, ASA Grade > 2, Contraindications to spinal anesthesia, bleeding disorder, thyroid disease, Addison’s disease, Parkinson’s disease, Raynaud’s syndrome. History of convulsions/epilepsy, bronchial asthma, allergy to the agents to be used, blood transfusion during surgery, initial axillary temperature 37.5 °C , use of sedative-hypnotic agents, vasodilators, antidepressants therapy with selective serotonin reuptake inhibitors and monoamine oxidase inhibitors, benzodiazepines. or patients having inadequate Sub arachnoid blockade requiring supplementation by general anaesthesia

Design outcomes

Primary

MeasureTime frame
prevention of shivering

Secondary

MeasureTime frame
drug side effects

Countries

India

Contacts

Public ContactRishabh Sethi

Army Hospital R&R Delhi India

rish.set@gmail.com+919953309321

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026